These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 19553005)

  • 1. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
    Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
    Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.
    Cimas FJ; Callejas-Valera JL; Pascual-Serra R; García-Cano J; Garcia-Gil E; De la Cruz-Morcillo MA; Ortega-Muelas M; Serrano-Oviedo L; Gutkind JS; Sánchez-Prieto R
    Oncotarget; 2015 Dec; 6(42):44095-107. PubMed ID: 26689986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
    Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II.
    Sung CH; Im HJ; Park N; Kwon Y; Shin S; Ye DJ; Cho NH; Park YS; Choi HK; Kim D; Chun YJ
    Toxicol Lett; 2013 Nov; 223(2):109-15. PubMed ID: 24055520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
    Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking of PI3K/AKT induces apoptosis by its effect on NF-κB activity in gastric carcinoma cell line SGC7901.
    Chao X; Zao J; Xiao-Yi G; Li-Jun M; Tao S
    Biomed Pharmacother; 2010 Nov; 64(9):600-4. PubMed ID: 20947290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
    Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
    Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
    Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
    Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent blockade of the NF-kappaB and Akt pathways potently sensitizes cancer cells to chemotherapeutic-induced cytotoxicity.
    He HN; Wang X; Zheng XL; Sun H; Shi XW; Zhong YJ; Huang B; Yang L; Li JK; Liao LC; Zhang L; Hu LN; Lin Y
    Cancer Lett; 2010 Sep; 295(1):38-43. PubMed ID: 20207071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo.
    Zhou B; Wang D; Sun G; Mei F; Cui Y; Xu H
    Cell Physiol Biochem; 2018; 46(3):999-1008. PubMed ID: 29669316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
    Karthik S; Sankar R; Varunkumar K; Anusha C; Ravikumar V
    Biomed Pharmacother; 2015 Feb; 69():337-44. PubMed ID: 25661379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.
    Song L; Xiong H; Li J; Liao W; Wang L; Wu J; Li M
    Clin Cancer Res; 2011 Apr; 17(7):1839-49. PubMed ID: 21325072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway.
    Ho FM; Lin WW; Chen BC; Chao CM; Yang CR; Lin LY; Lai CC; Liu SH; Liau CS
    Cell Signal; 2006 Mar; 18(3):391-9. PubMed ID: 15970429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells.
    Li B; Cheung PY; Wang X; Tsao SW; Ling MT; Wong YC; Cheung AL
    Carcinogenesis; 2007 Nov; 28(11):2313-20. PubMed ID: 17638919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460.
    Voortman J; Checinska A; Giaccone G; Rodriguez JA; Kruyt FA
    Mol Cancer Ther; 2007 Mar; 6(3):1046-53. PubMed ID: 17363497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activation of the NF-κB-JNK pathway is independent of the PI3K-Rac1-JNK pathway involved in the bFGF-regulated human fibroblast cell migration.
    Xuan Y; Chi L; Tian H; Cai W; Sun C; Wang T; Zhou X; Shao M; Zhu Y; Niu C; Sun Y; Cong W; Zhu Z; Li Z; Wang Y; Jin L
    J Dermatol Sci; 2016 Apr; 82(1):28-37. PubMed ID: 26829882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration.
    Lee MW; Kim DS; Lee JH; Lee BS; Lee SH; Jung HL; Sung KW; Kim HT; Yoo KH; Koo HH
    Cancer Sci; 2011 Oct; 102(10):1822-8. PubMed ID: 21722267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
    Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
    J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.